Economic analysis of finasteride: A model-based approach using data from the Proscarρ long-term efficacy and safety study

Clinical Therapeutics

Volumn 21, Issue 6, 1999, Pages 1006-1024

  Albertsen, Peter C ^a,b   Pellissier, James M ^b   Lowe, Franklin C ^c   Girman, Cynthia J ^b   Roehrborn, Claus G ^d  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d Merck Research Laboratories ^*

Author keywords

Benign prostatic hyperplasia; Cost minimization analysis; Finasteride; Proscar Long Term Efficacy and Safety Study; blockers

Indexed keywords

FINASTERIDE;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; MEDICAL DECISION MAKING; PROSTATE HYPERTROPHY;

EID: 0032771836     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80021-6     Document Type: Article

References (39)

1. 1. Guess HA. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1995;22:247-261.
2. 2. Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990;17:495-507.
3. 3. Oesterling JE. Benign prostatic hyperplasia: A review of its histogenesis and natural history. Prostate. 1996;6:67-73.
4. 4. McConnell JD, Barry MJ, Bruskewitz RC, et al. Clinical Practice Guideline Number 8: Benign Prostatic Hyperplasia: Diagnosis and Treatment. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1994. AHCPR Publication No. 94-0582.
5. 5. Goluboff ET, Olsson CA. Urologists on a tightrope: Coping with a changing economy. J Urol. 1994;151:1-4.
6. 6. Barry MJ, Fowler FJ, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
7. 7. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998;51:428-436.
8. 8. McConnell JD, Roehrborn CG. Patient selection and symptom evaluation. In: Chisholm GD, ed. Handbook on Benign Prostatic Hyperplasia. Whitehouse Station, NJ: Merck & Co., Inc; 1994.
9. 9. McConnell JD, Bruskewitz R, Walsh P, et al, and the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. NEJM. 1998;338:557-563.
10. 10. National Hospital Discharge Survey. Hyattsville, Md: US National Center for Health Statistics; 1995.
11. 11. Eri LM, Tveter KJ. α-Blockade in the treatment of symptomatic: benign prostatic hyperplasia. J Urol. 1996;154:923-934.
12. 12. Roberts RG. New guidelines based on symptoms and patient preference. The Agency for Health Care Policy and Research. Geriatrics. 1994;49:24-31.
13. 13. Andersen JT, Nickel JC, Marshall VR, et al. Finasteride significantly reduces acute urinary retention or the need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology. 1997;49:839-845.
14. 14. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology. 1996;48:398-405.
15. 15. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol. 1997;158:481-487.
16. 16. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate. 1990;16:253-261.
17. 17. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL. Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology. 1995;46:477-483.
18. 18. Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9:443-454.
19. 19. Cockrum PC, Finder SF, Ries AJ, Potyk RP. A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia. Pharmacoeconomics. 1997;11: 550-565.
20. 20. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia: W.B. Saunders; 1980.
21. 21. Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics Company; 1996.
22. 22. Department of Health and Human Services. Mortality, part A. In: Vital Statistics of the United States. Hyattsville, Md: US Dept of Health and Human Services; 1993;2:12.
23. 23. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology. 1996;47:159-168.
24. 24. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA. 1993;270:860-864.
25. 25. Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999; 53:581-589.
26. 26. Roehrborn CG, McConnell J, Lieber R, et al, for the PLESS Study Group. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with benign prostatic hyperplasia. Urology. 1999;53:473-480.
27. 27. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Hypertension, 1995; 26:60-69.
28. 28. St. Anthony's DKG Guidebook 1997. Reston, Va: St. Anthony Publishing; 1997.
29. 29. St. Anthony's APG Guidebook Version 2.0. Reston, Va: St. Anthony Publishing; 1997.
30. 30. Physician Fees: A Comprehensive Guide for Fee Schedule Review and Management. Los Angeles, Calif: Practice Management Information Corporation; 1997.
31. 31. 1997 St. Anthony's Complete RBRVS. Reston, Va: St. Anthony Publishing; 1997.
32. 32. 1997 Drug Topics Red Book. Montvale, NJ: Medical Economics Company, Inc; 1997.
33. 33. NPA Plus Retail Prescription Audit. Plymouth Meeting, Pa: IMS America; 1998.
34. 34. Lanes SF, Sulsky S, Walker AM, et al. A cost density analysis of benign prostatic hyperplasia. Clin Ther. 1996;18:993-1004.
35. 35. Lu-Yao GL, Barry MJ, Chang CH, et al, and the Prostate Patient Outcomes Research Team. Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Urology. 1994;44:692-699.
36. 36. Barry MJ, Fowler FJ, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol. 1997; 157:10-15.
37. 37. Denis L, Griffiths K, Khoury S, et al, eds. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia. Plymouth, UK: Health Publication Ltd; 1998.
38. 38. Copley-Merriman C, Lair TJ. Valuation of medical resource units collected in health economic studies. Clin Ther. 1994;16: 553-568.
39. 39. Cher DJ, Miyamoto J, Lenert LA. Incorporating risk attitude into Markov-process decision models: Importance for individual decision making. Med Decis Mak. 1997;17:340-350.